Cirrhosis of the Liver
10
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
Optimized Remission in Alcohol-related Liver Cirrhosis
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
Trial of Faecal Microbiota Transplantation in Cirrhosis
Frailty in Patients With Cirrhosis: Prognostic Value of the Phase Angle in Hospitalized Patients and Effect of Multifactorial Intervention
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
HRQoL in the Low MELD Pre-tx Population